Carol Bult
Professor and Knowlton Family Chair
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (9)
The poor clinical outcomes of pediatric high-grade glioma (pHGG) highlight the urgent need for new therapies. Oligodendrocyte lineage transcription factor 2 (OLIG2) is a pro-mitotic transcription factor highly expressed in glioma stem cells and may represent a novel therapeutic target. To evaluate the therapeutic efficacy of an OLIG2 inhibitor CT-179 in pHGG, we determined the OLIG2 mRNA expression in 10 patient-derived orthotopic xenograft (PDOX) models. In vitro activities of CT-179 were analyzed in monolayer and neurosphere cells (0–10 µM) with and without radiation (XRT) (0–8 Gy), brain penetration was evaluated in tumor-bearing PDOX mice, and in vivo efficacy was determined at 15–240 mg/kg (oral) alone or combined with XRT (2 Gy/day × 5 days). Changes in animal survival times were analyzed using the Kaplan–Meier method, followed by pair-wise comparisons. Increased OLIG2 mRNA expression was detected in seven out of ten PDOX models. CT-179 inhibited cell viability in a time- and dose-dependent manner in all eight pGBM xenograft tumors (IC50 0.03–10 µM) and was potentiated by XRT (0.03–1 µM). Oral gavage (24 mg/kg) of CT-179 for 5 days led to effective penetration in mouse cerebrum (3232.7 ± 569.2 ng/g), cerebellum (1563.3 ± 269.6 ng/g), brain stem (1685.3 ± 309 ng/g), and PDOX tumors (1814 ± 110.3 ng/g) vs. 361.3 ± 1.5 ng/mL in serum. CT-179 alone was not active at 200 mg/kg in four models, although it was moderately effective at 240 mg/kg in one model. When combined with XRT, a significant extension of animal survival times was observed in two out of four models. Doses needed to eliminate OLIG2 expression in vitro varied from 0.3 to >1 µM in pGBM cells. In summary, our data showed that orally administered CT-179 penetrated the blood–brain barrier (BBB) and exhibited potential for inhibiting pGBM growth when combined with XRT.
Year:
2026
Congenital diaphragmatic hernia (CDH) is a severe congenital anomaly characterized by impairment of both diaphragm and lung development in utero. CDH presents as a spectrum of forms and severities, with diaphragm defects arising in the dorsal/posterior region typically correlating with more severe pulmonary disease and higher risk of mortality than those appearing in ventral/anterior regions. The genetic etiology underlying CDH is complex, with many genes implicated showing variable expressivity and incomplete penetrance in both human patients and mouse models. Here we present in vivo validation of two genes previously unassociated with CDH: the CDC42-interacting kinase CDC42BPB; and CNOT1, a scaffolding protein of the CCR4-NOT protein complex, critical for mRNA regulation through modifications such as deadenylation. Each gene was found to have a damaging, de novo missense variant in a recent large-scale CDH patient sequencing screen. Loss of Cdc42bpb leads to ventral diaphragmatic hernias, heart septal defects and minor lung epithelial differentiation defects in mouse embryos. Installation of the orthologous patient-specific missense variant through CRISPR/Cas9 editing leads to less severe ventral diaphragm defects. Mouse embryos with either one or two copies of the orthologous Cnot1 variant, c.1867C>T (p.R623W), develop dorsal diaphragmatic hernias with low (<50%) penetrance, and mutants showed alterations in mRNA isoform expression consistent with the molecular role of Cnot1 in RNA splicing. These results underscore the power of in vivo functional modeling to validate genes and patient-specific variants uncovered by patient sequencing, reveal two previously unrecognized genetic causes of CDH, and highlight the heterogeneity of different patient anatomic presentations.
Year:
2026
Pediatric sarcomas present diagnostic challenges due to their rarity and diverse subtypes, often requiring specialized pathology expertise and costly genetic tests. To overcome these barriers, we developed a computational pipeline leveraging deep learning methods to accurately classify pediatric sarcoma subtypes from digitized histology slides. To ensure classifier generalizability and minimize center-specific artifacts, a dataset comprising 867 whole slide images (WSIs) from three medical centers and the Children's Oncology Group (COG) was collected and harmonized. Multiple convolutional neural network (CNN) and vision transformer (ViT) architectures were systematically evaluated as feature extractors for SAMPLER-based WSI representations, and input parameters, such as tile size combinations and resolutions, were tested and optimized. The analysis showed that advanced ViT foundation models (UNI, CONCH) significantly outperformed earlier approaches, and incorporating multiscale features enhanced classification accuracy. The optimized models achieved high performance, distinguishing rhabdomyosarcoma (RMS) from non-rhabdomyosarcoma (NRSTS) with an AUC of 0.969 and differentiating RMS subtypes (alveolar vs. embryonal) with an AUC of 0.961. Additionally, a two-stage pipeline effectively identified scarce Ewing sarcoma images from other NRSTS (AUC 0.929). Compared to conventional transformer encoder architectures used for WSI representations, these SAMPLER based classifiers were three orders of magnitude faster to train, despite operating entirely without a GPU. This study highlights that digital histopathology paired with rigorous image harmonization provides a powerful solution for pediatric sarcoma classification.
Year:
2026
Introduction Identifying key characteristics of exemplar genomic learning healthcare systems (gLHS) and knowledge gaps that can be explored by collaboration among them is likely to accelerate the sharing of best practices and generation of evidence that informs the use of genomics in clinical care. Methods Deliberations of an expert group convened by the National Human Genome Research Institute (NHGRI) supplemented by relevant literature. Results Recent advances in genomic data standardization, automated clinical decision support, increased interoperability, and improved genomic technologies have enabled the development of several robust gLHS . They remain concentrated in major academic centers, however, and operate largely independently. Sharing their methods and tools would increase access to these innovations and advance the field. Several gLHS have expressed willingness to collaborate in a coalition designed to gather, evaluate, and disseminate best practices and development needs. Such a coalition has recently been formed under the leadership of NHGRI. Conclusion Increased collaboration, interoperability, and sharing of genomic information and strategies across gLHS can help define, refine, and disseminate best practices. Such cooperation can improve genomic variant curation and interpretation, diagnostic accuracy, evidence generation, and ultimately patient care through seamless integration of research as an integral component of good clinical care.
Year:
2025
Purpose Pediatric sarcomas are rare and diverse, often leading to misclassification that hampers prognosis and treatment planning. We collected and harmonized histology images from multiple medical centers and developed accurate, generalizable classifiers for sarcoma subtype classification using deep learning techniques on digitized histology slides. Experimental Design A pediatric sarcoma histology dataset was amassed from three medical centers as well as the Children’s Oncology Group (COG), and a computational pipeline was implemented to address batch effects and standardize processing. Input parameter combinations (e.g. tile size, multi-scale feature extraction) were tested and optimized, and multiple convolutional neural network (CNN) and vision transformer-based (ViT) deep learning backbones were used as feature extractors for our SAMPLER whole slide image (WSI) representations, which we benchmarked to create an optimized, sarcoma-specific workflow. Models were trained for automated classification of rhabdomyosarcoma (RMS) versus non-rhabdomyosarcoma (NRSTS) and to further distinguish subtypes including alveolar, embryonal and spindle cell RMS as well as Ewing sarcoma. Results A total of 867 whole slide images were harmonized to generate a digital histology library with representation from 10 pediatric sarcoma subtypes. Across multiple classification tasks, ViT are superior to CNN models and multiscale feature sets consistently outperform single-scale models. Optimized classifiers accurately predicted RMS versus NRSTS (AUC 0.969±0.026) as well as alveolar versus embryonal RMS (AUC 0.961±0.021). Our two-stage classifier distinguished Ewing sarcoma from other NRSTS (AUC 0.929). Additionally, our models are computationally more lightweight than standard transformer implementations (model size 0.111 v. 1.9MB, training time > 3 orders of magnitude faster). Conclusions Digital histopathology can successfully classify pediatric sarcomas, providing results that are reproducible, mitigate inter-observer bias, and can be implemented remotely. We demonstrate that image harmonization overcomes the pitfall of overfitting to single institutional data while maintaining state-of-the-art performance across multiple classification tasks. The developed classifiers provide a basis for more precise histology-based sarcoma diagnostics, enabling global access to improved prognostication and treatment planning. Abstract Pediatric sarcomas present diagnostic challenges due to their rarity and diverse subtypes, often requiring specialized pathology expertise and costly genetic tests. To overcome these barriers, we developed a computational pipeline leveraging deep learning methods to accurately classify pediatric sarcoma subtypes from digitized histology slides. To ensure classifier generalizability and minimize center-specific artifacts, we collected and harmonized a dataset comprising 867 whole slide images (WSIs) from three medical centers and the Children’s Oncology Group (COG). Multiple convolutional neural network (CNN) and vision transformer (ViT) architectures were systematically evaluated as feature extractors for SAMPLER-based WSI representations, and input parameters such as tile size combinations and resolutions were tested and optimized. Our analysis showed that advanced ViT foundation models (UNI, CONCH) significantly outperformed earlier approaches, and incorporating multiscale features can enhance classification accuracy. Our optimized models achieved high performance, distinguishing rhabdomyosarcoma (RMS) from non-rhabdomyosarcoma (NRSTS) with an AUC of 0.969±0.026 and differentiating RMS subtypes (alveolar vs. embryonal) with an AUC of 0.961±0.021. Additionally, a two-stage pipeline effectively identified scarce Ewing sarcoma images from other NRSTS (AUC 0.929). Compared to conventional transformer encoder architectures used for WSI representations, our SAMPLER based classifiers were more lightweight (0.111 MB vs. 1.9 MB) and thr
Year:
2025
Summary Short tandem repeat (STR) profiling is commonly performed for authentication of biomedical models of human origin, yet no tools exist to easily compare sets of STR profiles to each other or an existing database in a high-throughput manner. Here, we present STRprofiler, a Python package, command line tool, and Shiny application providing methods for STR profile comparison and cross-contamination detection. STRprofiler can be run with custom databases or used to query against the Cellosaurus cell line database. Availability and implementation STRprofiler is freely available as a Python package with a rich CLI from PyPI https://pypi.org/project/strprofiler/ with source code available under the MIT license on GitHub https://github.com/j-andrews7/strprofiler and at https://zenodo.org/records/10989034. A web server hosting an example STRprofiler Shiny application backed by a database with data from the National Cancer Institute-funded PDXNet consortium and The Jackson Laboratory PDX program is available at https://sj-bakerlab.shinyapps.io/strprofiler/. Full documentation is available at https://strprofiler.readthedocs.io/en/latest/.
Year:
2024
Patient-derived xenografts (PDX) model human intra- and intertumoral heterogeneity in the context of the intact tissue of immunocompromised mice. Histologic imaging via hematoxylin and eosin (H&E) staining is routinely performed on PDX samples, which could be harnessed for computational analysis. Prior studies of large clinical H&E image repositories have shown that deep learning analysis can identify intercellular and morphologic signals correlated with disease phenotype and therapeutic response. In this study, we developed an extensive, pan-cancer repository of >1,000 PDX and paired parental tumor H&E images. These images, curated from the PDX Development and Trial Centers Research Network Consortium, had a range of associated genomic and transcriptomic data, clinical metadata, pathologic assessments of cell composition, and, in several cases, detailed pathologic annotations of neoplastic, stromal, and necrotic regions. The amenability of these images to deep learning was highlighted through three applications: (i) development of a classifier for neoplastic, stromal, and necrotic regions; (ii) development of a predictor of xenograft-transplant lymphoproliferative disorder; and (iii) application of a published predictor of microsatellite instability. Together, this PDX Development and Trial Centers Research Network image repository provides a valuable resource for controlled digital pathology analysis, both for the evaluation of technical issues and for the development of computational image–based methods that make clinical predictions based on PDX treatment studies. Significance: A pan-cancer repository of >1,000 patient-derived xenograft hematoxylin and eosin–stained images will facilitate cancer biology investigations through histopathologic analysis and contributes important model system data that expand existing human histology repositories.
Year:
2024
Patient-derived xenografts (PDX) model human intra- and intertumoral heterogeneity in the context of the intact tissue of immunocompromised mice. Histologic imaging via hematoxylin and eosin (H&E) staining is routinely performed on PDX samples, which could be harnessed for computational analysis. Prior studies of large clinical H&E image repositories have shown that deep learning analysis can identify intercellular and morphologic signals correlated with disease phenotype and therapeutic response. In this study, we developed an extensive, pan-cancer repository of >1,000 PDX and paired parental tumor H&E images. These images, curated from the PDX Development and Trial Centers Research Network Consortium, had a range of associated genomic and transcriptomic data, clinical metadata, pathologic assessments of cell composition, and, in several cases, detailed pathologic annotations of neoplastic, stromal, and necrotic regions. The amenability of these images to deep learning was highlighted through three applications: (i) development of a classifier for neoplastic, stromal, and necrotic regions; (ii) development of a predictor of xenograft-transplant lymphoproliferative disorder; and (iii) application of a published predictor of microsatellite instability. Together, this PDX Development and Trial Centers Research Network image repository provides a valuable resource for controlled digital pathology analysis, both for the evaluation of technical issues and for the development of computational image–based methods that make clinical predictions based on PDX treatment studies. Significance: A pan-cancer repository of >1,000 patient-derived xenograft hematoxylin and eosin–stained images will facilitate cancer biology investigations through histopathologic analysis and contributes important model system data that expand existing human histology repositories.
Year:
2024
Patient-derived xenografts (PDX) model human intra- and intertumoral heterogeneity in the context of the intact tissue of immunocompromised mice. Histologic imaging via hematoxylin and eosin (H&E) staining is routinely performed on PDX samples, which could be harnessed for computational analysis. Prior studies of large clinical H&E image repositories have shown that deep learning analysis can identify intercellular and morphologic signals correlated with disease phenotype and therapeutic response. In this study, we developed an extensive, pan-cancer repository of >1,000 PDX and paired parental tumor H&E images. These images, curated from the PDX Development and Trial Centers Research Network Consortium, had a range of associated genomic and transcriptomic data, clinical metadata, pathologic assessments of cell composition, and, in several cases, detailed pathologic annotations of neoplastic, stromal, and necrotic regions. The amenability of these images to deep learning was highlighted through three applications: (i) development of a classifier for neoplastic, stromal, and necrotic regions; (ii) development of a predictor of xenograft-transplant lymphoproliferative disorder; and (iii) application of a published predictor of microsatellite instability. Together, this PDX Development and Trial Centers Research Network image repository provides a valuable resource for controlled digital pathology analysis, both for the evaluation of technical issues and for the development of computational image–based methods that make clinical predictions based on PDX treatment studies. Significance: A pan-cancer repository of >1,000 patient-derived xenograft hematoxylin and eosin–stained images will facilitate cancer biology investigations through histopathologic analysis and contributes important model system data that expand existing human histology repositories.
Year:
2024
Collaborators (33)
Matthew H Bailey
Assistant Professor
Brigham Young University
Yufeng Shen
Columbia University
Michael A. Davies
-
Sherri Davies
Senior Scientist
Washington University in St. Louis
Samuel Rowbotham
Assistant Professor
Massachusetts General Hospital
Peter Robinson
Professor for Medical Computer Science
The Jackson Laboratory for Genomic Medicine
Jeffrey Chuang
Jackson Laboratory
Emily Christison-Lagay
Yale University
Xiaowei Xu
Professor
University of Pennsylvania
Clifford Stephan
Research Associate Professor
Texas A&M University Health Sciences Center
Shidan Wang
-
Junya Fujimoto
Professor and Chair
Hiroshima University Hospital
Alana Welm
Chair
Huntsman Cancer Institute
Nicholas Mitsiades
Professor
University of California, Davis
Bryan Welm
Associate Professor
Huntsman Cancer Institute
Meenhard Herlyn
Professor, Director
The Wistar Institute
Shunqiang Li
Associate Professor
Washington University in St. Louis
Peter Hulick
NorthShore University HealthSystem
Ryan C. Fields
University of Rochester
Luis G Carvajal‐Carmona
Professor
University of California, Davis
Xiao-Nan Li
Professor
Northwestern University
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Robert Mashl
Washington University in St. Louis
Chong-xian Pan
Professor
university of california davis medical center
Wendy Chung
Kennedy Family Professor
Boston Children's Hospital
Eleanor Chen
Assistant Professor
University of Washington
Salma Kaochar
Assistant Professor
Baylor College of Medicine
Li Ding
Associate Professor
Washington University in Saint Louis School of Medicine
Michael Lewis
Baylor College of Medicine
Maria Gabriela Raso
Assistant Professor
The University of Texas MD Anderson Cancer Center
Soner Koc
GlaxoSmithKline Research and Development
Guanghua Xiao
-
Yang Xie
Professor
University of Texas Southwestern Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.